Passa al contenuto
Merck
Tutte le immagini(2)

Key Documents

GF58573648

Lutetium

powder, 1g, max. particle size 500 micron, 99.9%

Sinonimo/i:

Lutetium, LU006010

Autenticatiper visualizzare i prezzi riservati alla tua organizzazione & contrattuali


About This Item

Formula empirica (notazione di Hill):
Lu
Numero CAS:
Peso molecolare:
174.97
Numero MDL:
Codice UNSPSC:
11101711
ID PubChem:
NACRES:
NA.23

Saggio

99.9%

Forma fisica

powder

Produttore/marchio commerciale

Goodfellow 585-736-48

Resistività

54 μΩ-cm, 20°C

Dimensione particelle

500 μm

P. eboll.

3402 °C (lit.)

Punto di fusione

1663 °C (lit.)

Densità

9.84 g/mL at 25 °C (lit.)

Stringa SMILE

[Lu]

InChI

1S/Lu
OHSVLFRHMCKCQY-UHFFFAOYSA-N

Cerchi prodotti simili? Visita Guida al confronto tra prodotti

Descrizione generale

For updated SDS information please visit www.goodfellow.com.

Note legali

Product of Goodfellow

Pittogrammi

Flame

Avvertenze

Danger

Indicazioni di pericolo

Classi di pericolo

Flam. Sol. 1

Codice della classe di stoccaggio

4.1B - Flammable solid hazardous materials

Classe di pericolosità dell'acqua (WGK)

WGK 3

Punto d’infiammabilità (°F)

Not applicable

Punto d’infiammabilità (°C)

Not applicable


Scegli una delle versioni più recenti:

Certificati d'analisi (COA)

Lot/Batch Number

Ci dispiace, ma al momento non ci sono COA disponibili online per questo prodotto.

Se ti serve aiuto, non esitare a contattarci Servizio Clienti

Possiedi già questo prodotto?

I documenti relativi ai prodotti acquistati recentemente sono disponibili nell’Archivio dei documenti.

Visita l’Archivio dei documenti

R O Perez et al.
Techniques in coloproctology, 18(8), 699-708 (2014-02-11)
Molecular imaging using positron emission tomography/computerized tomography (PET/CT) may add relevant incremental diagnostic information to standard structural cross-sectional imaging. Such information may allow identification of patients with rectal cancer that are more likely to develop complete tumor regression after neoadjuvant
B L R Kam et al.
European journal of nuclear medicine and molecular imaging, 39 Suppl 1, S103-S112 (2012-03-06)
Treatment with radiolabelled somatostatin analogues is a promising new tool in the management of patients with inoperable or metastasized neuroendocrine tumours. Symptomatic improvement may occur with (177)Lu-labelled somatostatin analogues that have been used for peptide receptor radionuclide therapy (PRRT). The
S Panigone et al.
The quarterly journal of nuclear medicine and molecular imaging : official publication of the Italian Association of Nuclear Medicine (AIMN) [and] the International Association of Radiopharmacology (IAR), [and] Section of the Society of..., 50(4), 310-321 (2006-10-18)
Optimization of therapy for individual patients remains a goal of clinical practice. Radionuclide imaging can identify those patients who may benefit from subsequent targeted therapy by providing regional information on the distribution of the target. An ideal situation may be
Constantin Lapa et al.
Nuclear medicine and biology, 42(4), 349-354 (2015-01-18)
Peptide receptor radionuclide therapy (PRRT) is a treatment option for both iodine-refractory differentiated and advanced medullary thyroid cancer (TC). It requires over-expression of somatostatin receptor subtype II (SSTR) that can be non-invasively assessed by positron emission tomography (PET). Assessment of
Constantin Lapa et al.
Annals of medicine, 47(7), 538-545 (2015-10-30)
Brown adipose tissue (BAT) attracts growing interest as a potential therapeutic target for obesity and diabetes. Hyperthyroidism is well-known to increase BAT activity, but the role of hypothyroidism is controversial. We aimed to investigate the association between different thyroid hormone

Il team dei nostri ricercatori vanta grande esperienza in tutte le aree della ricerca quali Life Science, scienza dei materiali, sintesi chimica, cromatografia, discipline analitiche, ecc..

Contatta l'Assistenza Tecnica.